Quick Answer
Glucotrack, Inc. reported Cash and Equivalents of $7.38 million for fiscal year 2025.
Glucotrack, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $7.38M | +31.4% |
| 2024 | $5.62M | +25.0% |
| 2023 | $4.49M | +94.3% |
| 2022 | $2.31M | -61.9% |
| 2021 | $6.06M | -38.3% |
| 2020 | $9.82M | +2244.4% |
| 2019 | $419.0K | +331.6% |
| 2018 | $97.1K | +80.5% |
| 2017 | $53.8K | -63.9% |
| 2016 | $148.8K | -75.5% |
| 2015 | $608.7K | -89.6% |
| 2014 | $5.83M | +144.2% |
| 2013 | $2.39M | +339.1% |
| 2012 | $543.4K | -71.3% |
| 2011 | $1.90M | +26.9% |
| 2010 | $1.49M | +2308.8% |
| 2009 | $62.0K | -88.2% |
| 2008 | $526.3K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $7.87M | +2174.3% | -17.6% |
| June 30, 2025 | $9.55M | +5909.4% | +5.0% |
| March 31, 2025 | $9.10M | +507.9% | +62.0% |
| December 31, 2024 | $5.62M | +25.0% | +1523.4% |
| September 30, 2024 | $346.0K | -95.0% | +117.6% |
| June 30, 2024 | $159.0K | -98.2% | -89.4% |
| March 31, 2024 | $1.50M | +49.3% | -66.7% |
| December 31, 2023 | $4.49M | +94.3% | -34.8% |
- Glucotrack, Inc. showed an increase of +31.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, Glucotrack, Inc.’s cash and equivalents has grown by 1302.8% (from $526.3 thousand to $7.38 million).
- The most recent figure is from Glucotrack, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: